Bustamante, Jhan G.

HRN: 23-24-90  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/21/2023
08/27/2023
IV
48mg
Q24
Tc Sepsis
Waiting Final Action 
08/21/2023
CEFTRIAXONE 1G (VIAL)
08/21/2023
08/27/2023
IV
320mg
Q24
Tc Sepsis
Waiting Final Action 
08/25/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/25/2023
08/31/2023
IV
320mg
Q8
Sepsis
Waiting Final Action 
08/27/2023
CLARITHROMYCIN 125MG/5ML, 60ML SUSPENSION (BOT)
08/27/2023
09/03/2023
ORAL
1ml
Q12
PCAP C; TC Sepsis
Waiting Final Action 
08/28/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
08/28/2023
09/03/2023
IV
30mg
Q8
Sepsis
Waiting Final Action 
08/31/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/31/2023
09/06/2023
IV
50mg
Q24
PCAP C
Waiting Final Action 
09/03/2023
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
09/03/2023
09/09/2023
IV
65mg LD, 20mg Maintenance
OD
Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: